4-quinolones inhibit biotransformation of caffeine
- PMID: 2853056
- DOI: 10.1007/BF00637602
4-quinolones inhibit biotransformation of caffeine
Erratum in
- Eur J Clin Pharmacol 1989;36(1):100
Abstract
The pharmacokinetics of caffeine, including formation of its major metabolite paraxanthine in plasma, has been investigated in 12 healthy males (age 20-40 years) alone and during co-administration of the 4-quinolones ofloxacin, norfloxacin, pipemidic acid, ciprofloxacin, and enoxacin; ciprofloxacin and enoxacin were given in 3 different dose levels. The naphthyridine derivative enoxacin and the pyrido-pyrimidine derivative pipemidic acid had caused marked inhibition of caffeine and paraxanthine metabolism, whereas the genuine quinolone derivatives norfloxacin and ciprofloxacin had little effect, and the pyrido-benzoxacine derivative ofloxacin had no detectable effect. The different molecular and spatial structures of the compounds appear to be responsible for the differences in inhibitory potency.
Similar articles
-
Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition.Eur J Clin Pharmacol. 1990;39(1):63-9. doi: 10.1007/BF02657060. Eur J Clin Pharmacol. 1990. PMID: 2177401
-
In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes.Antimicrob Agents Chemother. 1990 Apr;34(4):594-9. doi: 10.1128/AAC.34.4.594. Antimicrob Agents Chemother. 1990. PMID: 2344166 Free PMC article.
-
Effect of quinolones on caffeine disposition.Clin Pharmacol Ther. 1989 Mar;45(3):234-40. doi: 10.1038/clpt.1989.23. Clin Pharmacol Ther. 1989. PMID: 2920498 Clinical Trial.
-
The effects of quinolones on xanthine pharmacokinetics.Am J Med. 1992 Apr 6;92(4A):22S-25S. doi: 10.1016/0002-9343(92)90303-s. Am J Med. 1992. PMID: 1580270 Review.
-
Overview of the fluoroquinolone antibiotics.Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):4S-17S. Pharmacotherapy. 1993. PMID: 8386356 Review.
Cited by
-
Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients.Antimicrob Agents Chemother. 1991 Jun;35(6):1137-41. doi: 10.1128/AAC.35.6.1137. Antimicrob Agents Chemother. 1991. PMID: 1929255 Free PMC article. Clinical Trial.
-
Effect of ciprofloxacin on the pharmacokinetics of ropivacaine.Eur J Clin Pharmacol. 2003 Feb;58(10):653-7. doi: 10.1007/s00228-002-0540-8. Epub 2003 Jan 29. Eur J Clin Pharmacol. 2003. PMID: 12610740 Clinical Trial.
-
Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.Korean J Physiol Pharmacol. 2017 Jan;21(1):107-115. doi: 10.4196/kjpp.2017.21.1.107. Epub 2016 Dec 21. Korean J Physiol Pharmacol. 2017. PMID: 28066147 Free PMC article.
-
PK-DB: pharmacokinetics database for individualized and stratified computational modeling.Nucleic Acids Res. 2021 Jan 8;49(D1):D1358-D1364. doi: 10.1093/nar/gkaa990. Nucleic Acids Res. 2021. PMID: 33151297 Free PMC article.
-
Effects of moderate exercise on the pharmacokinetics of caffeine.Eur J Clin Pharmacol. 1991;40(3):279-82. doi: 10.1007/BF00315209. Eur J Clin Pharmacol. 1991. PMID: 2060565
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical